NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did not respond to two or more previous treatments.
Novartis’ groundbreaking cancer T-cell therapy CTL019 has won unanimous backing from advisers to the FDA, paving the way for approval in the coming months. There had been concerns that the ...
The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...
A cancer therapy that uses genetically engineered immune cells, called CAR T-cells, has kept a person free of a potentially fatal nerve tumour for a record-breaking 18 years. “This is ...
Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...
We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to ...
A woman who received CAR-T-cell therapy has now been in cancer remission for 19 years. Plus, a genetic swap makes mice squeak differently.
Researchers have harnessed synthetic biology to engineer chimeric antigen receptor (CAR) T cells that precisely target and destroy cancer. However, these powerful cells can also attack healthy tissues ...
Galapagos NV’s split could unlock value despite short-term share decline. Learn why GLPG stock’s strategic focus offers ...
The Global Cancer Immunotherapy Market achieved a valuation of $121.2 Billion in 2023 and is anticipated to exceed $245.37 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果